Gilead expands Hepatitis C drug licensing pacts with Indian firms

New Delhi, Aug 28: Gilead's drug Gileas

aramine has expanded in Hepatitis C genetic licensing agreements with India-based firms to include investiga-
tional pan-genotypic medi-
cine ledipasvir as part of a single tablet regimen that combines it with sofosbuvir.

The commercial DMM India subsidiary, Gilead's in
e India, will work with the part-
ners as part of a single

sofosbuvir and the single tablet regimen of ledipasvir/50 mg/s/o, once ap-
poved, for distribution in all developing countries..." it added.

These countries together account for 80% of the total
worldwide population of in-
dividuals infected with the
hepatitis C virus, it added.

Commenting on the develop-
ment, Gilead Sciences Corpo-
rate and Medical Affairs
Chief Executive Officer Brad Garlovski
said, "Today's announcement is a
significant step in our

Gilead currently has licensing agreements for Hepatitis C drugs with eight India-based
firms — Cipla, Ranbaxy, Cadila, Mylan Laboratories, Sequent Scientific, Strides Arcolab, Biocion and Hetero Labs — to manufacture generic versions of sofosbuvir and investigational single tablet regimen of ledipasvir/sofosbuvir for distribution.

Gilead Sciences and its licensing partners will work under the terms negotiated by the US Food and Drug Administration (FDA) in December 2013 and the European Commission in January 2014. These licensing agreements include ledipasvir/sofosbuvir across the major geographic regions for hepatitis C, Gilead said. Gileas has also recently reached regulatory approval

ledipasvir/sofosbuvir treatment regimens.